549 related articles for article (PubMed ID: 26136569)
21. Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents.
Tuttle DL; Coberley CR; Xie X; Kou ZC; Sleasman JW; Goodenow MM
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):305-13. PubMed ID: 15117454
[TBL] [Abstract][Full Text] [Related]
22. A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors.
Hoffman TL; Canziani G; Jia L; Rucker J; Doms RW
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11215-20. PubMed ID: 11005830
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure.
Holm GH; Zhang C; Gorry PR; Peden K; Schols D; De Clercq E; Gabuzda D
J Virol; 2004 May; 78(9):4541-51. PubMed ID: 15078935
[TBL] [Abstract][Full Text] [Related]
24. HIV coreceptor usage and drug treatment.
Regoes R; Bonhoeffer S
J Theor Biol; 2002 Aug; 217(4):443-57. PubMed ID: 12234752
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
26. Concordant utilization of macrophage entry coreceptors by related variants within an HIV type 1 primary isolate viral swarm.
Singh A; Yi Y; Isaacs SN; Kolson DL; Collman RG
AIDS Res Hum Retroviruses; 2001 Jul; 17(10):957-63. PubMed ID: 11461681
[TBL] [Abstract][Full Text] [Related]
27. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).
Agrawal L; Vanhorn-Ali Z; Alkhatib G
J Leukoc Biol; 2002 Nov; 72(5):1063-74. PubMed ID: 12429730
[TBL] [Abstract][Full Text] [Related]
28. Substitutions in a homologous region of extracellular loop 2 of CXCR4 and CCR5 alter coreceptor activities for HIV-1 membrane fusion and virus entry.
Chabot DJ; Broder CC
J Biol Chem; 2000 Aug; 275(31):23774-82. PubMed ID: 10827088
[TBL] [Abstract][Full Text] [Related]
29. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4.
Lee B; Doranz BJ; Rana S; Yi Y; Mellado M; Frade JM; Martinez-A C; O'Brien SJ; Dean M; Collman RG; Doms RW
J Virol; 1998 Sep; 72(9):7450-8. PubMed ID: 9696841
[TBL] [Abstract][Full Text] [Related]
30. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.
Chabot DJ; Zhang PF; Quinnan GV; Broder CC
J Virol; 1999 Aug; 73(8):6598-609. PubMed ID: 10400757
[TBL] [Abstract][Full Text] [Related]
31. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
32. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
33. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
Dragic T; Trkola A; Thompson DA; Cormier EG; Kajumo FA; Maxwell E; Lin SW; Ying W; Smith SO; Sakmar TP; Moore JP
Proc Natl Acad Sci U S A; 2000 May; 97(10):5639-44. PubMed ID: 10779565
[TBL] [Abstract][Full Text] [Related]
34. Fusion Stage of HIV-1 Entry Depends on Virus-Induced Cell Surface Exposure of Phosphatidylserine.
Zaitseva E; Zaitsev E; Melikov K; Arakelyan A; Marin M; Villasmil R; Margolis LB; Melikyan GB; Chernomordik LV
Cell Host Microbe; 2017 Jul; 22(1):99-110.e7. PubMed ID: 28704658
[TBL] [Abstract][Full Text] [Related]
35. Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.
Mulampaka SN; Dixit NM
PLoS One; 2011; 6(5):e19941. PubMed ID: 21647388
[TBL] [Abstract][Full Text] [Related]
36. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.
Harmon B; Campbell N; Ratner L
PLoS Pathog; 2010 Jun; 6(6):e1000956. PubMed ID: 20585556
[TBL] [Abstract][Full Text] [Related]
37. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2001 Nov; 75(22):11096-105. PubMed ID: 11602749
[TBL] [Abstract][Full Text] [Related]
38. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
[TBL] [Abstract][Full Text] [Related]
39. A CCR5/CXCR4-independent coreceptor pathway on human macrophages supports efficient SIV env-mediated fusion but not infection: implications for alternative pathways of viral entry.
Yi Y; Singh A; Isaacs SN; Collman RG
Virology; 2001 May; 284(1):142-51. PubMed ID: 11352675
[TBL] [Abstract][Full Text] [Related]
40. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
Olson WC; Rabut GE; Nagashima KA; Tran DN; Anselma DJ; Monard SP; Segal JP; Thompson DA; Kajumo F; Guo Y; Moore JP; Maddon PJ; Dragic T
J Virol; 1999 May; 73(5):4145-55. PubMed ID: 10196311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
